CN101934030A - Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same - Google Patents
Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same Download PDFInfo
- Publication number
- CN101934030A CN101934030A CN2010102698819A CN201010269881A CN101934030A CN 101934030 A CN101934030 A CN 101934030A CN 2010102698819 A CN2010102698819 A CN 2010102698819A CN 201010269881 A CN201010269881 A CN 201010269881A CN 101934030 A CN101934030 A CN 101934030A
- Authority
- CN
- China
- Prior art keywords
- radix
- diabetes
- thirst
- quench
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title abstract description 7
- 208000024891 symptom Diseases 0.000 title abstract description 3
- 206010020710 Hyperphagia Diseases 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 238000001035 drying Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000005469 granulation Methods 0.000 claims abstract description 6
- 230000003179 granulation Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 32
- 239000008517 radix Trichosanthis Substances 0.000 claims description 22
- 230000035922 thirst Effects 0.000 claims description 21
- 238000010791 quenching Methods 0.000 claims description 20
- 241000208340 Araliaceae Species 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 32
- 239000008280 blood Substances 0.000 abstract description 31
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 241000699670 Mus sp. Species 0.000 abstract description 10
- 201000001421 hyperglycemia Diseases 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000099774 Cuscuta salina Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 229940102884 adrenalin Drugs 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 28
- 210000004072 lung Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 241000219780 Pueraria Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Based on the main treating principle of tonifying qi and yin, nourishing spleen and tonifying kidney and promoting blood circulation and removing blood stasis, the invention provides a medicinal composition for treating symptom-complex of excessive eating (diabetes) and a method for preparing the same, and belongs to the technical field of Chinese medicinal preparations. In the method, astragalus, ginseng, manyflower solomonseal rhizome, Chinese magnoliavine fruit, fresh rehmannia, dwarf lilyturf tuber, medlar, golden thread, kudzuvine root, Chinese angelica, Mongolian snakegourd root and root of red-rooted salvia serving as raw materials undergo processes of grinding, solvent extraction, alcohol precipitation, condensation, drying, granulation and the like to form the finished product. The pharmacodynamic tests prove that by pharmacotherapeutic administration, the medicinal composition of the invention has obvious effect of reducing blood sugar of rats with tetraoxypyridine-induced hyperglycemia, mice with tetraoxypyridine-induced hyperglycemia and mice with adrenalin-induced hyperglycemia.
Description
Technical field
The present invention relates to a kind of treatment the quench one's thirst pharmaceutical composition and the preparation method of (diabetes), belong to the Chinese medicine preparation technical field.Be particularly useful for treating clinically type ii diabetes.
Background technology
Diabetes are traditional Chinese medical science diabetes, the sickness rate height, and the course of disease is long, easily causes heart disease, cerebral infarction, complication such as blind.Modern medicine is thought a kind of metabolism endocrinopathy, and the water-electrolyte metabolism of the sugar, fat, protein and the secondary that cause is disorderly to be feature owing to the absolute deficiency of insulin or relative deficiency and pancreatic function reduce.Clinically based on lasting blood sugar increasing and glucose in urine.At present the medicine of treatment diabetes is divided into three major types: 1, Western medicine, such medicine is with the sulfonylurea of insulin, the second filial generation such as glibenclamide, glipizide, Glipizide controlled release tablets, gliclazide, glibornuride and gliquidone etc., third generation glimepiride.Its main mechanism is that specificity suppresses adenosine triphosphate (ATP) dependency potassium channel on the beta Cell of islet film, causes the film depolarization, and the calcium ion concentration that impels intracellular voltage to rely on raises, thereby increases beta Cell of islet secretion and uelralante.But after this class of prolonged application medicine, its hypoglycemic activity may be to increase the quantity of Insulin receptor INSR or increase insulin binding power, thereby increased the sensitivity of surrounding tissue to insulin, the advantage of this class medicine is that controlling symptoms is rapid, evident in efficacy, but side effect is obvious, especially to the damage of liver, renal function or take the patient for a long time and insulin sensitivity is reduced and produce drug resistance; 2, in, western bound drug, " in a diabetes pill " that such medicine is produced with Guangzhou No.1 Chinese Pharmacy Factory is representative, main component has the Radix Astragali, the Radix Rehmanniae, Radix Trichosanthis and Western medicine glibenclamide, this medical instrument has YIN nourishing to support the fast characteristics of kidney, supplementing QI for promoting the production of body fluid and curative effect, but contain the Western medicine of 0.25mg in every ball, thereby the patient who remains at damage liver, renal function produces chemical sproof deficiency.3, Chinese medicine, theory of Chinese medical science that the treatment type ii diabetes is used such as benefiting qi and nourishing yin, invigorating the spleen to clear away damp pathogen, depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling or the like all have different hypoglycemic activities.
Two just do many years ago relevant for the record of quenching one's thirst with three types of diabetes in motherland's theory of medicine.The function of pancreas is within the scope of spleen.Says in " element is asked the passages through which vital energy circulates another matter ": " drink is gone into stomach, transporting essential substances in solution, on fail in spleen, temper diffusing through on fail in lung." cyclic process of hence one can see that body fluid, quenching one's thirst is the fortuneization that body fluid has lost spleen, makes dryness of the lung heat and thirsty.Say in " medical science newspeak three types of diabetes ": " person's of disappearing double its kidney of controlling of its stomach clearly is controled the inferior the person of disappearing and should be grown its lung of the double benefit of its kidney in controlling for the person of disappearing in the big ruling by law, its lung of Yi Run clear its stomach of holding concurrently." be the guiding principle of TCM treatment of diabetes.
The theory of the Chinese medicine of medicinal application described in the present invention diabetes based on supplementing QI and nourishing YIN, the kidney invigorating of taste spleen, has blood circulation promoting and blood stasis dispelling concurrently.With Radix Astragali invigorating the spleen and replenishing QI, yang invigorating, help temper to rise in the side, multiple its diffusing essence reaches the duty of lung; Radix Ginseng strongly invigorating primordial QI, YIN nourishing and the production of body fluid promoting, quench the thirst; Radix Puerariae yang invigorating expelling pathogenic factors from muscles, relieving restlessness three medicines that quench the thirst are played the merit that supplementing QI and nourishing YIN is grown spleen the kidney invigorating arresting seminal emission altogether, so be monarch drug, pharmacology proves that the Radix Astragali can reduce free radical generation, promotion free radical scavenging; Radix Ginseng and effective ingredient thereof have preventive and therapeutic effect to renal failure, and Radix Puerariae can obviously improve renal blood flow, anticoagulant and reduction blood viscosity; Fructus Schisandrae Chinensis astringe the lung nourishing kidney, QI invigorating and promote the production of body fluid; The Radix Rehmanniae YIN nourishing and the production of body fluid promoting is quenched the thirst; Radix Ophiopogonis nourishing lung-YIN, reinforcing stomach reg fluid; Fructus Lycii the kidney invigorating lung moistening; Rhizoma Coptidis is nourshing Yin and drynsessmoistening prescription, clearing heat and relieving fidgetness; Radix Trichosanthis is supported the moon of lung stomach kidney, and promoting the production of body fluid to quench thirst, pathogenic fire reducing are moisturized and be ministerial drug.The Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind makes the QI and blood smoothness, reduces blood viscosity, and microcirculation improvement improves hypoglycemic effect; Radix Salviae Miltiorrhizae water-soluble composition salvianolic acid A can suppress fibroblast proliferation, and it is synthetic to reduce fibrocyte collagen, effectively alleviates tissue fibering; Chinese angelica blood supplementing and blood, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae promoting the circulation of blood blood stasis removing, the detoxifcation of nourishing blood is adjuvant drug; Rhizoma Polygonati is the gas of tonifying the lung kidney both, and the moon of spleen reinforcing lung kidney is messenger drug again, and all medicines are harmonious, and spleen invigorating is not and dry, and nourishing kidney is and oiliness, and inspiration is clear positive, gas in the vibrations, and do not have dry fraud just, play supplementing QI and nourishing YIN, the kidney invigorating of taste spleen, the effect of blood circulation promoting and blood stasis dispelling altogether.
Summary of the invention
The present invention is with traditional Chinese medical science supplementing QI and nourishing YIN, the kidney invigorating of taste spleen, and being aided with blood circulation promoting and blood stasis dispelling is main Therapeutic Principle, the pharmaceutical composition and the preparation method that provide a kind of treatment to quench one's thirst (diabetes).
Technical scheme of the present invention is achieved in that the quench one's thirst pharmaceutical composition of (diabetes) of treatment, and its crude drug proportion of composing (w/w) comprises Radix Astragali 200-400 part, Radix Ginseng 50-150 part, Radix Puerariae 500-250 part, Fructus Schisandrae Chinensis 50-200 part, Radix Rehmanniae 50-250 part, Radix Ophiopogonis 50-250 part, Rhizoma Coptidis 50-150 part, Radix Salviae Miltiorrhizae 50-250, Radix Angelicae Sinensis 100-300 part, Rhizoma Polygonati 100-300 part.
The quench one's thirst pharmaceutical composition of (diabetes) of described treatment, the proportion of composing of its crude drug (w/w) comprises 300 parts of the Radixs Astragali, 100 parts of Radix Ginsengs, 150 parts of Radix Puerariaes, 100 parts of Fructus Schisandrae Chinensis, 150 parts of Radix Rehmanniae, 150 parts of Radix Ophiopogonis, 100 parts of Rhizoma Coptidis, Radix Salviae Miltiorrhizae 150,200 parts of Radix Angelicae Sinensis, 200 parts of Rhizoma Polygonatis.
The quench one's thirst pharmaceutical composition of (diabetes) of described treatment, the proportion of composing of its crude drug (w/w) also comprises Radix Trichosanthis 50-250 part, Fructus Lycii 50-250 part.
The quench one's thirst pharmaceutical composition of (diabetes) of described treatment, the ratio of described crude drug (w/w) comprises 300 parts of the Radixs Astragali, 100 parts of Radix Ginsengs, 150 parts of Radix Puerariaes, 100 parts of Fructus Schisandrae Chinensis, 150 parts of Radix Rehmanniae, 150 parts of Radix Ophiopogonis, 100 parts of Rhizoma Coptidis, Radix Salviae Miltiorrhizae 150,200 parts of Radix Angelicae Sinensis, 200 parts of Rhizoma Polygonatis, 150 parts of Radix Trichosanthis, 150 parts of Fructus Lycii.
The quench one's thirst preparation of drug combination method of (diabetes) of above-mentioned treatment is as follows:
(1) Radix Trichosanthis is ground into fine powder and crosses 100 mesh sieves, and is standby;
(2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn;
(3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, and standing over night is got supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize behind the vacuum drying or spraying drying powder-forming, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, with the general ball of 95-50% ethanol, promptly get pill; Or use the 95-50% alcohol granulation, drying, tabletting or fill capsule or make granule.
Following the applicant will illustrate that this medicine has the effect for the treatment of quench one's thirst (diabetes) and describes by concrete pharmacodynamics test.
Pharmacodynamics test
1 material
1.1 medicine extract of the present invention: self-control; Lot number 20080412; JIANGTANGSHU sheet: the safe Pharmaceutical in sky, Jilin Province limited company 86903423001282); Alloxan: U.S. sigma company; Adrenalin hydrochloride: Shandong Xinhua Pharmaceutical Factory.
1.2ABBOTT-CCX, automatic clinical chemistry analyzer, the U.S. produces; The β liquid scintillation counter, the U.S. produces; 721 spectrophotometers, last marine products.
1.3 male Wistar rat, body weight 180-220g, male mice in kunming, body weight 20 ± 2g is provided by Guangdong Medical Lab Animal Center.
2 methods and result
2.1 influence to experimental diabetes disease model blood glucose
2.1.1 alloxan rat hyperglycemia influenced 60 of male Wistar rats, 10 is normal control, all the other rat fasting are tail vein injection alloxan 40mg/kg after 14 hours, inject and get fasting blood after 48 hours, use the determination of glucose oxidase blood sugar content, by the blood glucose value grouping (blood glucose value is not rejected 17-27mmol/L scope person) that raises, every group 10, be respectively the alloxan matched group, the heavy dose of group of extract of the present invention 4g/kg, small dose group 1g/kg, JIANGTANGSHU group 3g/kg, every day, gastric infusion was 1 time, normal control group and alloxan matched group give isometric(al) normal saline (following test is identical), successive administration 10 days is got blood in the last administration and is surveyed blood glucose value after 1 hour, the result does the t check and sees Table 1.
Table 1 extract of the present invention is to the influence (X ± SD n:10) of alloxan hyperglycemia
Annotate: " * " expression is compared * P＜0.05 with the alloxan matched group; * P＜0.01
The result shows that the present invention has obvious suppression effect (P＜0.01) to rat alloxan hyperglycemia.
2.1.2 influence to alloxan mice hyperglycemia
80 of male mice in kunming, 10 is normal control, all the other mice fasting are tail vein injection alloxan 70mg/kg after 20 hours, injects and gets fasting blood survey blood glucose value after 40 hours, is equally divided into 4 groups (blood glucose value is not rejected 10-80mmol/L scope person) by the blood sugar increasing value, every group 13, be respectively alloxan matched group, the heavy dose of group of the present invention, small dose group, the JIANGTANGSHU group, every day, gastric infusion was 1 time, successive administration is got blood and is surveyed blood glucose value after 20 days, the result does the t check and sees Table 2.
Table 2 extract of the present invention is to the influence of alloxan mice hyperglycemia (mmol/L, x ± SD)
Annotate: " * " expression is compared * * P＜0.01 with the alloxan group
The result shows that the present invention can obviously suppress alloxan mouse blood sugar rising (P＜0.01).
2.1.3 influence to adrenal gland's disposition mice hyperglycemia
Male mice in kunming is divided into 5 groups by weight average, be respectively the normal control group, epinephrine matched group, the heavy dose of group of the present invention, small dose group and JIANGTANGSHU group, every day, gastric infusion was 1 time, successive administration 10 days, in the last administration after 1 hour, all the other respectively organize mouse peritoneal injection epinephrine 0.2mg/kg except that the normal control group, inject and get blood survey blood glucose value after 1 hour, and the result does the t check and sees Table 3.
Table 3 extract of the present invention is to the influence of adrenal gland's disposition mice hyperglycemia (mmol/L, X ± SD)
Annotate: " * " expression is compared * * P＜0.01 with the epinephrine matched group
The result shows that the present invention can obviously suppress adrenal gland's disposition mouse blood sugar rising (P＜0.01).
The specific embodiment
Further specify the present invention below in conjunction with embodiment, but this can not think limitation of the present invention.
Embodiment one:
The Radix Astragali 300 gram Radix Ginsengs 100 gram Radix Puerariaes 150 gram Fructus Schisandrae Chinensis 100 grams
Radix Rehmanniae 150 gram 150 gram Rhizoma Coptidis Radix Ophiopogonis 100 gram Radix Salviae Miltiorrhizaes 150 grams
Radix Angelicae Sinensis 200 gram Rhizoma Polygonatis 200 gram Radix Trichosanthis 150 gram Fructus Lycii 150 grams
Preparation method
(1) Radix Trichosanthis is ground into fine powder and crosses 100 mesh sieves, and is standby;
(2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn;
(3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, and standing over night is got supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize behind the vacuum drying or spraying drying powder-forming, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, with the general ball of 95-50% ethanol, promptly get pill.
Embodiment two:
The Radix Astragali 340 gram Radix Ginsengs 80 gram Radix Puerariaes 200 gram Fructus Schisandrae Chinensis 100 grams
Radix Rehmanniae 100 gram 150 gram Rhizoma Coptidis Radix Ophiopogonis 80 gram Radix Salviae Miltiorrhizaes 200 grams
Radix Angelicae Sinensis 200 gram Rhizoma Polygonatis 300 gram Radix Trichosanthis 150 gram Fructus Lycii 150 grams
Preparation method
(1) Radix Trichosanthis is ground into fine powder and crosses 100 mesh sieves, and is standby;
(2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn;
(3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, standing over night, get supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize or spraying drying powder-forming behind the vacuum drying, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, use the 95-50% alcohol granulation, drying, tabletting.
Embodiment three:
The Radix Astragali 250 gram Radix Ginsengs 150 gram Radix Puerariaes 250 gram Fructus Schisandrae Chinensis 150 grams
Radix Rehmanniae 150 gram 150 gram Rhizoma Coptidis Radix Ophiopogonis 100 gram Radix Salviae Miltiorrhizaes 150 grams
Radix Angelicae Sinensis 200 gram Rhizoma Polygonatis 200 gram Radix Trichosanthis 150 gram Fructus Lycii 150 grams
Preparation method
(1) Radix Trichosanthis is ground into fine powder and crosses 100 mesh sieves, and is standby;
(2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn;
(3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, standing over night, get supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize or spraying drying powder-forming behind the vacuum drying, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, use the 95-50% alcohol granulation, drying, fill capsule.
Embodiment four:
The Radix Astragali 200 gram Radix Ginsengs 50 gram Radix Puerariaes 200 gram Fructus Schisandrae Chinensis 150 grams
Radix Rehmanniae 150 gram 150 gram Rhizoma Coptidis Radix Ophiopogonis 100 gram Radix Salviae Miltiorrhizaes 150 grams
Radix Angelicae Sinensis 300 gram Rhizoma Polygonatis 300 gram Radix Trichosanthis 150 gram Fructus Lycii 150 grams
Preparation method
(1) Radix Trichosanthis is ground into fine powder and crosses 100 mesh sieves, and is standby;
(2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn;
(3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, standing over night, get supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize or spraying drying powder-forming behind the vacuum drying, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, use the 95-50% alcohol granulation, drying is made granule.
Claims (6)
1. the treatment pharmaceutical composition of (diabetes) of quenching one's thirst, its crude drug proportion of composing (w/w) comprise Radix Astragali 50-400 part, Radix Ginseng 20-150 part, Radix Puerariae 30-250 part, Fructus Schisandrae Chinensis 20-200 part, Radix Rehmanniae 50-400 part, Radix Ophiopogonis 50-300 part, Rhizoma Coptidis 50-150 part, Radix Salviae Miltiorrhizae 50-250, Radix Angelicae Sinensis 50-300 part, Rhizoma Polygonati 50-300 part.
2. the quench one's thirst pharmaceutical composition of (diabetes) of treatment according to claim 1, the proportion of composing (w/w) that it is characterized in that described crude drug comprise Radix Astragali 100-350 part, Radix Ginseng 50-120 part, Radix Puerariae 50-200 part, Fructus Schisandrae Chinensis 50-150 part, Radix Rehmanniae 100-350 part, Radix Ophiopogonis 80-250 part, Rhizoma Coptidis 60-120 part, Radix Salviae Miltiorrhizae 80-200 part, Radix Angelicae Sinensis 100-250 part, Rhizoma Polygonati 100-250 part.
3. the quench one's thirst pharmaceutical composition of (diabetes) of treatment according to claim 1 is characterized in that the proportion of composing (w/w) of described crude drug also comprises Radix Trichosanthis 100-400 part, Fructus Lycii 50-250 part.
4. according to the quench one's thirst pharmaceutical composition of (diabetes) of claim 1,2 or 3 described treatments, the proportion of composing (w/w) that it is characterized in that described crude drug comprises Radix Astragali 100-350 part, Radix Ginseng 50-120 part, Radix Puerariae 50-200 part, Fructus Schisandrae Chinensis 50-150 part, Radix Rehmanniae 100-350 part, Radix Ophiopogonis 80-250 part, Rhizoma Coptidis 60-120 part, Radix Salviae Miltiorrhizae 80-200 part, Radix Angelicae Sinensis 100-250 part, Rhizoma Polygonati 100-250 part, Radix Trichosanthis 150-350 part, Fructus Lycii 80-200 part.
5. according to the quench one's thirst pharmaceutical composition of (diabetes) of claim 1,2,3 or 4 described treatments, it is characterized in that: said medicament is a said dosage form on any pharmaceutics.
6. according to the quench one's thirst preparation method of (diabetes) medicine of claim 1,2 or 4 described a kind of treatments, it is characterized in that: be ground into fine powder by described proportioning (1) Radix Trichosanthis and cross 100 mesh sieves, standby; (2) Rhizoma Coptidis, Fructus Schisandrae Chinensis, Radix Angelicae Sinensis are doubly measured the 50-95% alcohol reflux 2 times with 16-4, distinguish 1-4 hour, merge extractive liquid, at every turn; (3) all the other Radix Ginsengs, the Radix Astragali, Rhizoma Polygonati, Radix Rehmanniae, Radix Ophiopogonis, Fructus Lycii, Radix Puerariae, Radix Salviae Miltiorrhizae totally eight flavors add water 14-6 and doubly measure, soak, heating decocts 2 times, merge decoction liquor, it is an amount of to add 60-95% ethanol, and standing over night is got supernatant, with (a 2) extracting solution merging down, be evaporated to the thick paste shape, pulverize behind the vacuum drying or spraying drying powder-forming, add after above-mentioned Radix Trichosanthis fine powder or suitable adjuvant fully mix, with the general ball of 95-50% ethanol, promptly get pill; Or use the 95-50% alcohol granulation, drying, tabletting or fill capsule or make granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102698819A CN101934030A (en) | 2010-08-28 | 2010-08-28 | Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102698819A CN101934030A (en) | 2010-08-28 | 2010-08-28 | Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101934030A true CN101934030A (en) | 2011-01-05 |
Family
ID=43387751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102698819A Pending CN101934030A (en) | 2010-08-28 | 2010-08-28 | Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101934030A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178733A (en) * | 2011-03-29 | 2011-09-14 | 中国中医科学院中医临床基础医学研究所 | Chinese medicinal preparation for treating diabetes and preparation method thereof |
| CN104137992A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Health-care food capable of decreasing blood sugar and preparing method of health-care food |
| CN104208603A (en) * | 2013-05-29 | 2014-12-17 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine for treating diabetes and preventing cardio-cerebrovascular complications and preparation method thereof |
| CN104938728A (en) * | 2015-07-20 | 2015-09-30 | 青海省通天河藏药制药有限责任公司 | Preparation method of substitutional tea for reducing blood glucose |
| CN105497281A (en) * | 2016-01-21 | 2016-04-20 | 范峰苑 | Traditional Chinese medicine formula for treating diabetes |
| CN107929431A (en) * | 2018-01-05 | 2018-04-20 | 张虹华 | Traditional Chinese medicine formula of tea substitute for drinking for treating diabetes and decocting method thereof |
| CN108126101A (en) * | 2018-03-05 | 2018-06-08 | 中国人民解放军第四军医大学 | It is a kind of to be used to treat pharmaceutical preparation of diabetic cardiomyopathy and preparation method thereof |
| CN108236667A (en) * | 2016-12-24 | 2018-07-03 | 郑州市天地人农副产品有限公司 | It quenches one's thirst mind-tranquilizing formulation |
| CN108403957A (en) * | 2018-06-06 | 2018-08-17 | 王宝民 | A kind of Chinese medicine preparation and preparation method thereof for treating diabetes and complication |
| CN109221867A (en) * | 2018-10-08 | 2019-01-18 | 康学春 | A kind of rhizoma polygonati corn stigma Radix Astragali solid beverage and preparation method thereof |
| CN110613792A (en) * | 2019-09-19 | 2019-12-27 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN110787258A (en) * | 2019-11-27 | 2020-02-14 | 王同生 | A Chinese medicinal composition for treating diabetes, and its preparation method |
| CN111617184A (en) * | 2020-05-16 | 2020-09-04 | 新疆万德昌生物有限公司 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN112999308A (en) * | 2021-03-05 | 2021-06-22 | 山西康寿茶业有限公司 | Blood sugar reducing tea formula and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100319A (en) * | 1994-01-19 | 1995-03-22 | 李仲岭 | Pancreatic islet recovering capsule and its preparing method |
| CN1190025A (en) * | 1998-02-16 | 1998-08-12 | 沈存正 | Diabetes therapeutic equipment |
| US6093403A (en) * | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
| CN101366908A (en) * | 2008-08-11 | 2009-02-18 | 李丽 | Traditional Chinese medicine for treating diabetes |
| CN101664504A (en) * | 2008-09-03 | 2010-03-10 | 刘爱莲 | Medicament for treating diabetes and preparation method thereof |
-
2010
- 2010-08-28 CN CN2010102698819A patent/CN101934030A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100319A (en) * | 1994-01-19 | 1995-03-22 | 李仲岭 | Pancreatic islet recovering capsule and its preparing method |
| US6093403A (en) * | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
| CN1190025A (en) * | 1998-02-16 | 1998-08-12 | 沈存正 | Diabetes therapeutic equipment |
| CN101366908A (en) * | 2008-08-11 | 2009-02-18 | 李丽 | Traditional Chinese medicine for treating diabetes |
| CN101664504A (en) * | 2008-09-03 | 2010-03-10 | 刘爱莲 | Medicament for treating diabetes and preparation method thereof |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178733B (en) * | 2011-03-29 | 2013-05-29 | 中国中医科学院中医临床基础医学研究所 | Chinese medicinal preparation for treating diabetes and preparation method thereof |
| CN102178733A (en) * | 2011-03-29 | 2011-09-14 | 中国中医科学院中医临床基础医学研究所 | Chinese medicinal preparation for treating diabetes and preparation method thereof |
| CN104208603A (en) * | 2013-05-29 | 2014-12-17 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine for treating diabetes and preventing cardio-cerebrovascular complications and preparation method thereof |
| CN104137992A (en) * | 2014-07-29 | 2014-11-12 | 卞佳林 | Health-care food capable of decreasing blood sugar and preparing method of health-care food |
| CN104137992B (en) * | 2014-07-29 | 2015-10-21 | 卞佳林 | A kind of hypoglycemia healthcare food and preparation method thereof |
| CN104938728A (en) * | 2015-07-20 | 2015-09-30 | 青海省通天河藏药制药有限责任公司 | Preparation method of substitutional tea for reducing blood glucose |
| CN105497281A (en) * | 2016-01-21 | 2016-04-20 | 范峰苑 | Traditional Chinese medicine formula for treating diabetes |
| CN108236667A (en) * | 2016-12-24 | 2018-07-03 | 郑州市天地人农副产品有限公司 | It quenches one's thirst mind-tranquilizing formulation |
| CN107929431A (en) * | 2018-01-05 | 2018-04-20 | 张虹华 | Traditional Chinese medicine formula of tea substitute for drinking for treating diabetes and decocting method thereof |
| CN108126101A (en) * | 2018-03-05 | 2018-06-08 | 中国人民解放军第四军医大学 | It is a kind of to be used to treat pharmaceutical preparation of diabetic cardiomyopathy and preparation method thereof |
| CN108403957A (en) * | 2018-06-06 | 2018-08-17 | 王宝民 | A kind of Chinese medicine preparation and preparation method thereof for treating diabetes and complication |
| CN109221867A (en) * | 2018-10-08 | 2019-01-18 | 康学春 | A kind of rhizoma polygonati corn stigma Radix Astragali solid beverage and preparation method thereof |
| CN110613792A (en) * | 2019-09-19 | 2019-12-27 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN110613792B (en) * | 2019-09-19 | 2021-12-24 | 中南大学湘雅二医院 | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof |
| CN110787258A (en) * | 2019-11-27 | 2020-02-14 | 王同生 | A Chinese medicinal composition for treating diabetes, and its preparation method |
| CN111617184A (en) * | 2020-05-16 | 2020-09-04 | 新疆万德昌生物有限公司 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN112999308A (en) * | 2021-03-05 | 2021-06-22 | 山西康寿茶业有限公司 | Blood sugar reducing tea formula and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101934030A (en) | Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same | |
| CN1325102C (en) | Ready prepared Chinese medicine for treating diabetes | |
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN102302563B (en) | Chinese medicinal composition for treating chronic kidney failure and preparation method thereof | |
| CN103566350A (en) | Pharmaceutical composition having blood sugar reducing effect | |
| CN103127158B (en) | Cyclocarya paliurus extract and application thereof | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN102872376B (en) | Traditional Chinese medicine composition for nursing or treating diabetic peripheral neuropathy pain | |
| CN102178733B (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN101317964A (en) | Chinese medicinal composition with spleen-enlivening and kidney-tonifying function, preparation and uses thereof | |
| CN102698100B (en) | Oral solution for treating diabetes mellitus | |
| CN103520376A (en) | Chinese medicine health-maintenance preparation with auxiliary hypoglycemic activity | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN102641489B (en) | Medicinal composition for treating acquired immune deficiency syndrome (Aids) as well as preparation method, quality control method and application thereof | |
| CN102552520B (en) | Blood circulation-promoting and pain-stopping medicament and preparation process and application thereof | |
| CN1973850B (en) | Medicine composition for treating allergic rhinitis and its preparation process | |
| CN102552861A (en) | Ginseng Sini granules and preparing method thereof | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN101259205A (en) | Medicaments assembly for treating adiposis and preparation thereof | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN104524156A (en) | Traditional Chinese medicine cataplasma for treating autoimmune thyroiditis | |
| CN103536806A (en) | Traditional Chinese medicine composition for treating alcoholic myocardiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGDONG JIAYING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHENG PEI Effective date: 20120719 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 519070 ZHUHAI, GUANGDONG PROVINCE TO: 514021 MEIZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120719 Address after: 514021 B District, Dongsheng Industrial Park, Guangdong, Meizhou Applicant after: Guangdong Jiaying Pharmaceutical Co., Ltd. Address before: Xiangzhou District of Guangdong city in Zhuhai province 519070 Qianshan Yixian Road No. 119 Building 2 room 404 Applicant before: Zheng Pei |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110105 |